Atara Biotherapeutics Files 8-K on Financials

Ticker: ATRA · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateMar 7, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

Related Tickers: ATRA

TL;DR

ATRA filed an 8-K on financials, check for updates.

AI Summary

On March 7, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing provides an update on Atara Biotherapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high or medium risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Atara Biotherapeutics, Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 07, 2025.

What is Atara Biotherapeutics, Inc.'s principal executive office address?

Atara Biotherapeutics, Inc.'s principal executive office is located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.

What is the company's telephone number?

The company's telephone number, including area code, is (805) 623-4211.

What is the Standard Industrial Classification code for Atara Biotherapeutics, Inc.?

The Standard Industrial Classification code for Atara Biotherapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing